In 2025, GlaxoSmithKline Pharmaceuticals disclosed key data related to its energy management practices, providing transparency into its operational energy use in line with recognized sustainability reporting frameworks.
GlaxoSmithKline Pharmaceuticals disclosed progress toward renewable energy adoption, highlighting the share of total energy sourced from renewable versus non-renewable sources.
| Metric (GJ) | 2025 | 2024 | 2023 | 2022 - 2017 |
|---|---|---|---|---|
Total Energy Consumption | 108,023a | 112,564a | N/A | |
Non-Renewable Energy Consumption | 55,479a | 59,181a | N/A | |
Renewable Energy Consumption | 52,543a | 53,383a | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore GlaxoSmithKline Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
In 2025, GlaxoSmithKline Pharmaceuticals consumed a total of 108,023 Gigajoules of energy across its operations. Of this total, 48.64% was sourced from renewable energy, either derived from natural resources like biofuels, biomass, or biogas, or generated using renewable technologies such as solar or wind power. The remaining 51.36% was classified as non-renewable energy, coming from fossil-based fuels such as coal, natural gas, or crude oil, or from non-renewable generation technologies like nuclear power.a
In 2025, GlaxoSmithKline Pharmaceuticals consumed a total of 108,023 Gigajoules of energy, of which 48.64% was derived from renewable sources, including biofuels, biomass, biogas, solar, and wind power.a
This moderate level of renewable energy adoption indicates that GlaxoSmithKline Pharmaceuticals is transitioning toward cleaner energy sources, though a significant share of its energy mix still relies on non-renewable inputs.
Since 2025, GlaxoSmithKline Pharmaceuticals's total energy consumption decreased by 4.03%, suggesting a recent decline in overall energy demand.a
Over the same period, the share of renewable energy in GlaxoSmithKline Pharmaceuticals's consumption increased by 2.56%, showing a recent positive trend in clean energy adoption.a